In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease.

Voyager will receive

Read the full 369 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE